Cargando…

Acute bilateral myopia induced by Triplixam: a case report

BACKGROUND: Side effects of the systemic drugs used to treat eyes are not common. Triplixam is used to treat systemic hypertension and contains amlodipine, indapamide and perindopril arginine as active ingredients which might have induced the sudden myopia. The transient myopia with objective findin...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaruseviciene, Ruta, Sirvydyte, Ginte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510128/
https://www.ncbi.nlm.nih.gov/pubmed/32962672
http://dx.doi.org/10.1186/s12886-020-01635-2
_version_ 1783585725824892928
author Jaruseviciene, Ruta
Sirvydyte, Ginte
author_facet Jaruseviciene, Ruta
Sirvydyte, Ginte
author_sort Jaruseviciene, Ruta
collection PubMed
description BACKGROUND: Side effects of the systemic drugs used to treat eyes are not common. Triplixam is used to treat systemic hypertension and contains amlodipine, indapamide and perindopril arginine as active ingredients which might have induced the sudden myopia. The transient myopia with objective findings disappeared after the discontinuation of the drug. CASE PRESENTATION: A 33-year-old male presented to the emergency department with a history of blurred vision in both eyes. Development of myopia, lens thickening, choroidal effusion and retinal striae at the macula with the increase in macular thickness was observed in both eyes. These symptoms cleared completely after the drug was discontinued. Myopisation could have been caused by lens thickening and changing its refractive index as a result of allergic or idiosyncratic reaction of the ciliary body. Retinal striae may be caused by the volume effect of the choroidal effusion. CONCLUSION: Our report describes the adverse effect of Triplixam, probably resulting from its ingredient indapamide. Although indapamide is a common drug used in the treatment of systemic hypertension, it is important for cardiologists, general practitioners and other physicians to be aware of the possible adverse effect of Triplixam.
format Online
Article
Text
id pubmed-7510128
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75101282020-09-24 Acute bilateral myopia induced by Triplixam: a case report Jaruseviciene, Ruta Sirvydyte, Ginte BMC Ophthalmol Case Report BACKGROUND: Side effects of the systemic drugs used to treat eyes are not common. Triplixam is used to treat systemic hypertension and contains amlodipine, indapamide and perindopril arginine as active ingredients which might have induced the sudden myopia. The transient myopia with objective findings disappeared after the discontinuation of the drug. CASE PRESENTATION: A 33-year-old male presented to the emergency department with a history of blurred vision in both eyes. Development of myopia, lens thickening, choroidal effusion and retinal striae at the macula with the increase in macular thickness was observed in both eyes. These symptoms cleared completely after the drug was discontinued. Myopisation could have been caused by lens thickening and changing its refractive index as a result of allergic or idiosyncratic reaction of the ciliary body. Retinal striae may be caused by the volume effect of the choroidal effusion. CONCLUSION: Our report describes the adverse effect of Triplixam, probably resulting from its ingredient indapamide. Although indapamide is a common drug used in the treatment of systemic hypertension, it is important for cardiologists, general practitioners and other physicians to be aware of the possible adverse effect of Triplixam. BioMed Central 2020-09-22 /pmc/articles/PMC7510128/ /pubmed/32962672 http://dx.doi.org/10.1186/s12886-020-01635-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Jaruseviciene, Ruta
Sirvydyte, Ginte
Acute bilateral myopia induced by Triplixam: a case report
title Acute bilateral myopia induced by Triplixam: a case report
title_full Acute bilateral myopia induced by Triplixam: a case report
title_fullStr Acute bilateral myopia induced by Triplixam: a case report
title_full_unstemmed Acute bilateral myopia induced by Triplixam: a case report
title_short Acute bilateral myopia induced by Triplixam: a case report
title_sort acute bilateral myopia induced by triplixam: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510128/
https://www.ncbi.nlm.nih.gov/pubmed/32962672
http://dx.doi.org/10.1186/s12886-020-01635-2
work_keys_str_mv AT jarusevicieneruta acutebilateralmyopiainducedbytriplixamacasereport
AT sirvydyteginte acutebilateralmyopiainducedbytriplixamacasereport